TrialMolecular cancer2025

Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, single center and biomarker exploratory, phase II study.

Yunxin Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.